B10.01 Human herpesvirus 6 encephalitis

Name of the Condition

• Human herpesvirus 6 encephalitis

Summary

Human herpesvirus 6 encephalitis is a rare neurological condition characterized by inflammation of the brain parenchyma due to infection with human herpesvirus 6 (HHV-6). It typically presents with acute or subacute neurological symptoms, including altered mental status, fever, and focal deficits. The condition requires prompt medical evaluation to manage potential complications and guide treatment.

Causes

Human herpesvirus 6 encephalitis is caused by the human herpesvirus 6 (HHV-6), a member of the Herpesviridae family. The virus can invade the central nervous system through primary infection or reactivation of latent virus, leading to inflammation and tissue damage. Transmission routes may include direct contact with infected bodily fluids or respiratory droplets, though specific mechanisms for encephalitis are not fully defined.

Risk Factors

• Immunocompromised states, such as HIV/AIDS, organ transplantation, or chemotherapy.
• Conditions that may reactivate latent HHV-6, including stress or immunosuppression.
• Close contact with individuals shedding the virus, though transmission to the brain is rare.

Symptoms

• Altered mental status, confusion, or disorientation.
• Fever and headache.
• Focal neurological deficits, such as weakness or sensory changes.
• Seizures or abnormal movements.
• Nausea, vomiting, or photophobia.

Diagnosis

Diagnosis involves a combination of clinical evaluation, neuroimaging (e.g., MRI or CT), and laboratory testing. Cerebrospinal fluid (CSF) analysis may show pleocytosis, elevated protein, or viral DNA via PCR. Neuroimaging often reveals characteristic brain abnormalities, such as temporal lobe involvement. Exclusion of other causes of encephalitis is essential for confirmation.

Treatment Options

Treatment typically includes antiviral therapy, such as ganciclovir or foscarnet, to target HHV-6. Supportive care, including antipyretics, seizure management, and intracranial pressure control, is often necessary. Immunocompromised patients may require prolonged or adjusted therapy. Consultation with infectious disease specialists is recommended.

Prognosis and Follow-Up

Prognosis varies based on severity, timely treatment, and underlying health status. Early intervention improves outcomes, but some patients may experience residual neurological deficits. Follow-up includes monitoring for symptom recurrence, cognitive function, and potential complications. Regular neurological assessments are advised.

Complications

• Persistent neurological deficits, such as memory loss or motor impairment.
• Seizure disorders or epilepsy.
• Increased intracranial pressure leading to brain herniation.
• Secondary infections due to immunosuppression.
• Long-term cognitive or behavioral changes.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Practice good hygiene, including handwashing, to reduce viral exposure.
• Avoid close contact with individuals showing signs of active HHV-6 infection.
• For immunocompromised individuals, adhere to medical guidance to prevent reactivation.

When to Seek Professional Help

Seek immediate medical attention if experiencing sudden neurological symptoms, such as confusion, severe headache, or seizures. Prompt evaluation is critical for early diagnosis and treatment. Contact a healthcare provider if symptoms worsen or new neurological signs appear.

Tips for Medical Coders

Document the clinical confirmation of human herpesvirus 6 encephalitis, including laboratory or imaging results supporting the diagnosis. Ensure the code B10.01 is used when the condition is specifically attributed to HHV-6. Include details of the patient’s immune status or underlying conditions if relevant to the encounter. Avoid using this code for encephalitis caused by other herpesviruses.